Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Harvard Apparatus Regenerative Medicine (OTCQB: HRGN) shares wrongful death lawsuit settlement with back story on Netflix

April 12, 2024

Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … <  > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants.  “There's just one problem: His patients kept dying.” Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations! Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!

RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results

April 2, 2024

A scorecard of earnings releases of covered companies -  The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 30 of 35 covered released to date    

RegMed Investors (RMi) research note – Finance: Sangamo Therapeutics (SGMO) Proposes Offering of 24,761,905 shares priced at $0.84

March 22, 2024

SGMO dived $0.1465 to $08238 or -15.098% And pre-funded warrants of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock priced at $0.83 Gross proceeds $24 M possible Barclays and Cantor are acting as placement agents for the offering